转移性结直肠癌系统治疗患者体重变化轨迹与生存的关联:ARCAD数据库汇总分析
基于1998至2006年五项3期随机试验中3504例初治转移性结直肠癌患者的个体数据,分析系统治疗期间体重变化与总生存和无进展生存的关联。3个月时体重下降<5%和≥5%者较体重稳定或增加者死亡风险升高,中位总生存分别为18.0和11.9个月对20.5个月。作者认为治疗中体重变化或可作为中间终点。
要点
- 体重下降程度与死亡风险增加呈线性趋势,在低体重、正常体重和肥胖者中均可见。
核心结论
- 转移性结直肠癌患者系统治疗期间体重下降与总生存显著缩短相关,下降程度与死亡风险增加成比例,在低体重、正常体重和肥胖个体中均可见。
- 作者认为治疗中体重变化或可作为中间终点。
研究设计与样本
- 对1998至2006年开展的五项3期随机试验中既往未治疗患者的个体数据进行分析,数据来自ARCAD数据库。
- 体重在基线和诊断后最长59.4个月内前瞻性采集,采用分层多因素Cox模型评估体重下降与总生存和无进展生存的预后关联并校正其他因素。
- 主要终点为体重下降人群与体重稳定或增加人群之间的总生存差异,共纳入3504例患者。
主要发现
- 3个月时体重变化中位数为-0.54%(IQR -3.9至+1.5%)。
- 未分层中位总生存:体重稳定或增加者20.5个月,3个月体重下降<5%者18.0个月,3个月体重下降≥5%者11.9个月(p<0.001)。
- 观察到体重进行性下降与死亡风险增加相关的线性趋势。
临床怎么用
- 作者认为治疗中体重变化或可作为中间终点。
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Higher body mass index is associated with a higher incidence of colorectal cancer (CRC) but also with improved survival in metastatic CRC (mCRC). Whether weight change after mCRC diagnosis is associated with survival remains largely unknown. METHODS: We analysed individual patient data for previously untreated patients enrolled in five phase 3 randomised trials conducted between 1998 and 2006. Weight measurements were prospectively collected at baseline and up to 59.4 months after diagnosis. We used stratified multivariable Cox models to assess the prognostic associations of weight loss with overall and progression-free survival, adjusting for other factors. The primary end-point was a difference in overall survival (OS) between populations with weight loss and stable or increasing weight. FINDINGS: Data were available for 3504 patients. The median weight change at 3 months was -0.54% (IQR -3.9 … +1.5%). We identified a linear trend of increasing risk of death associated with progressive weight loss. Unstratified median OS was 20.5, 18.0, and 11.9 months (p < 0.001) for stable weight or gain, <5% weight loss, and ≥5% weight loss at 3 months, respectively. Weight loss was associated with a higher risk of death (<5% loss: aHR 1.18 [1.06-1.30], p < 0.002; ≥5% loss: aHR 1.87 [1.67-2.1], p < 0.001) as compared to stable or increasing weight at 3 months post-baseline (reference), while adjusting for age, sex, performance, and a number of metastatic sites. INTERPRETATION: Patients losing weight during systemic therapy for metastatic colorectal cancer have significantly shorter OS. The degree of weight loss is proportional to the observed increased risk of death and remains evident among underweight, normal weight, and obese individuals. On-treatment weight change could be used as an intermediate end-point. FUNDING: The creation and management of the database containing the individual patient data from the original randomised trials is supported by the Aide et Recherche en Cancérologie Digestive Foundation.
引用
- Franko J, Yin J, Adams RA, et al. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. Eur J Cancer. 2022. PMID: 35994794. doi:10.1016/j.ejca.2022.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。